Share
85 Posts.
lightbulb Created with Sketch. 25
clock Created with Sketch. 30/11/23
21:33
Share
Originally posted by Davisite:
↑
In fairness to the Race management at the time, the 2023 Three Pillar approach is very innovative. The conventional approach is to advance Bisantrene primarily as an anticancer drug with cardioprotection properties. This involves picking a late stage cancer indication (say triple negative breast cancer) and then running a conventional 3+3 dose escalation Phase 1 trial followed by a standard Phase 2 in that indication with anticancer activity as the endpoint. It is not possible to measure cardioprotection conventionally until Phase 3 as you require around 2000 patients in total.
Expand
Can I ask you to comment on what kind of risk you see (if any) in pursuing a non conventional strategy when the goal is to achieve a transaction with large companies that tend to have a lot of bureaucracy and established processes for valuing opportunities? Some of the rationale behind the DCB strategy was to make it fit with the BP pipelines which made sense. Do you think the new strategy will make it more challenging when speaking with BP in this sense?
Last edited by
ReNova :
30/11/23
(20min delay)